US pharmaceutical giant Pfizer is looking to buy rare disease specialist Orphan Biovitrum AB, according to a Reuters report. The price that Pfizer has offered has not been disclosed. The Swedish company, known as Sobi, disclosed earlier this week that a potential buyer had made a preliminary offer.
Pfizer has established a Rare Disease Research Unit and sees drugs for rare diseases as an important opportunity in its mix of businesses, according to Reuters.
Pfizer has actively been looking at takeover targets after a failed attempt to buy rival British drugmaker AstraZeneca. It officially gave up on this project after its final $118 billion (£77.2 billion) bid was rejected on May 26th last year.
Pfizer downgrades profit forecast
The announcement comes as Pfizer cut its full-year revenue and profit forecast, blaming the stronger dollar. Its 2015 revenue forecast now ranges between $44 billion and $46 billion, from $44.5 billion and $46.5 billion. "The only thing that they lowered their guidance on … was all currency," Leerink Partners Pharma Analyst Seamus Fernandez told CNBC.
Meanwhile, it reported on Tuesday (April 28th) that Its first-quarter profit reached $2.38 billion, or 38 cents a share, up from $2.33 billion, or 36 cents a share, in the year-earlier period.
Pfizer's net profit rose to $2.38 billion, or 38 cents per share, for the quarter, from $2.33 billion, or 36 cents per share, a year earlier. Revenue fell 4.3 per cent to $10.86 billion.
Shares of the drugmaker remained flat at $34.62 in premarket trading.
GAIN Capital UK Limited (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.